Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction

This study has been completed.

Sponsor:

ClinicalTrials.gov Identifier:

NCT00935311

First Posted: July 9, 2009

Last Update Posted: April 8, 2014

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

Information provided by (Responsible Party):

AbbVie ( AbbVie (prior sponsor, Abbott) )

Results First Submitted: November 1, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Pain
Interventions:	Drug: ABT-712 Extended-release Drug: Hydrocodone/Acetaminophen Immediate-release Drug: Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
ABT-712	1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
Hydrocodone/Acetaminophen	2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
Placebo	2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).

Participant Flow: Overall Study

	ABT-712	Hydrocodone/Acetaminophen	Placebo
STARTED	43	39	40
COMPLETED	43	39	40
NOT COMPLETED	0	0	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
ABT-712	1 dose of 1 ABT-712 extended-release tablet plus 1 placebo tablet, followed by 1 dose of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
Hydrocodone/Acetaminophen	2 doses of 1 hydrocodone/acetaminophen immediate-release tablet plus 1 placebo tablet, administered once every 6 hours for 12 hours (for a total of 2 doses).
Placebo	2 doses of 2 placebo tablets, administered once every 6 hours for 12 hours (for a total of 2 doses).
Total	Total of all reporting groups

Baseline Measures

	ABT-712	Hydrocodone/Acetaminophen	Placebo	Total
Overall Participants Analyzed [Units: Participants]	43	39	40	122

Age [Units: Years] Mean (Standard Deviation)	22.1 (2.83)	21.4 (3.20)	23.0 (4.73)	22.2 (3.70)

Gender [Units: Participants]
Female	22	23	28	73
Male	21	16	12	49

Outcome Measures

Show All Outcome Measures

1. Primary:

Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS) [ Time Frame: From time of first study drug administration to 12 hours following first study drug administration ]

Show Outcome Measure 1

2. Secondary:

TOTPAR (Total Pain Relief) [ Time Frame: From time of first study drug administration to 12 hours following first study drug administration ]

Show Outcome Measure 2

3. Secondary:

Time to First Rescue Medication [ Time Frame: From time of first study drug administration to 12 hours following first study drug administration ]

Show Outcome Measure 3

4. Secondary:

Participants With Adverse Events (AEs) [ Time Frame: AEs were recorded from study drug administration until 30 days following discontinuation of study drug (total 30 days); SAEs were recorded from the time informed consent was obtained until 30 days following discontinuation of study drug (total 51 days). ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.

Results Point of Contact:

Name/Title: Global Medical Services
Organization: AbbVie (prior sponsor, Abbott)
phone: 800-633-9110

Responsible Party:	AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:	NCT00935311 History of Changes
Other Study ID Numbers:	M11-063
First Submitted:	June 29, 2009
First Posted:	July 9, 2009
Results First Submitted:	November 1, 2013
Results First Posted:	March 7, 2014
Last Update Posted:	April 8, 2014

To Top